FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vet Res Commun / Endometrial tissue concentrations of enrofloxacin after intr...
Veterinary research communications2002; 26(5); 371-380; doi: 10.1023/a:1016242812772

Endometrial tissue concentrations of enrofloxacin after intrauterine administration to mares.

Abstract: Endometritis in mares is a common cause of infertility. Conventional treatments of the disease have mostly been unsuccessful, so new therapeutic alternatives need to be investigated. This study evaluated the uterine disposition and plasma pharmacokinetic behaviour of a commercial formulation of enrofloxacin (EFX) given by the intrauterine (i.u.) route (2.5 mg/kg) in healthy mares. In order to evaluate the uterine inflammatory response, an initial histopathological study assessing polymorphonuclear cell infiltration was carried out in 20 mares over a 14-day period after treatment. In a second study, 6 healthy adult mares were used for the pharmacokinetic study. Samples of uterine tissue and plasma were collected from 0 to 24 h after the i.u. treatment with 5% EFX solution. Samples were analysed by conventional microbiological assay using an EFX-sensitive strain of Escherichia coli (ATCC 25922). There was a moderate but statistically nonsignificant inflammatory response following i.u. administration of either the formulation or the vehicle alone. Pharmacokinetic analysis of the uterine concentrations of EFX showed a slow and sustained depletion, with EFX remaining at concentrations above the MIC for 24 h after treatment. The area under the concentration-time curve obtained for the uterus suggested that EFX and its metabolites are specifically retained in the uterus, which is the target tissue for bacterial colonization. Neither study provided any evidence of EFX toxicity. In conclusion, these results are encouraging and suggest that EFX may be a useful local treatment in mares with bacterial endometritis.
Get Full Text
Publication Date: 2002-09-06 PubMed ID: 12212727DOI: 10.1023/a:1016242812772Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Clinical Trial
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article discusses the potential use of enrofloxacin (EFX), a commercial antibiotic, for the treatment of endometritis in mares. Endometritis is an inflammation of the uterus which can cause infertility. This study specifically looks into the effectiveness of intrauterine administration of EFX in treating the disease.

Study Methods and Procedures

  • An initial study was conducted where a histopathological analysis assessed the inflammatory response in the uterus of 20 mares over a 14-day period after treatment with enrofloxacin.
  • This was followed by a second study, which included 6 healthy adult mares. The aim was to examine the pharmacokinetic behavior, or how the drug is absorbed, distributed, metabolized, and excreted in the body.
  • For this purpose, samples of uterine tissue and plasma were collected at various time points up to 24 hours after intrauterine treatment with a 5% EFX solution. These samples were then analyzed using conventional microbiological assays.

Findings

  • From the initial study, a moderate but statistically non-significant inflammatory response was observed following the administration of EFX or the vehicle alone.
  • Findings from the pharmacokinetic study showed a slow depletion of EFX from the uterine tissues – the drug remained at concentrations above the MIC (minimum inhibitory concentration) for 24 hours after treatment. This suggests that EFX and its metabolites are specifically retained in the uterus – the target tissue for bacterial colonization.
  • Across both studies, no evidence of EFX toxicity was found.

Conclusion

  • The research provided promising results suggesting the potential use of enrofloxacin as a local treatment for mares with bacterial endometritis. Particularly, EFX’s retention in the uterus and its moderate inflammatory response present as notable highlights.
  • However, it is important to note that further comprehensive investigations would be needed before a definitive conclusion can be reached on EFX’s efficacy and safety in treating endometritis in mares.

Cite This Article

APA
Fumuso E, Checura C, Losinno L, Soto P, Sánchez S. (2002). Endometrial tissue concentrations of enrofloxacin after intrauterine administration to mares. Vet Res Commun, 26(5), 371-380. https://doi.org/10.1023/a:1016242812772

Publication

Veterinary research communications
ISSN: 0165-7380
NlmUniqueID: 8100520
Country: Switzerland
Language: English
Volume: 26
Issue: 5
Pages: 371-380

Researcher Affiliations

Fumuso, E
  • Area de Fisiopatología de al Reproducción, Facultad de Ciencias Veterinarias, Universidad Nacional del Centro de la Provincia de Buenos Aires, Tandil, Argentina.
Checura, C
    Losinno, L
      Soto, P
        Sánchez, S

          MeSH Terms

          • Animals
          • Anti-Infective Agents / administration & dosage
          • Anti-Infective Agents / blood
          • Anti-Infective Agents / metabolism
          • Anti-Infective Agents / pharmacokinetics
          • Area Under Curve
          • Endometrium
          • Enrofloxacin
          • Female
          • Fluoroquinolones
          • Horses
          • Microbial Sensitivity Tests
          • Organ Specificity
          • Quinolones / administration & dosage
          • Quinolones / blood
          • Quinolones / metabolism
          • Quinolones / pharmacokinetics
          • Tissue Distribution
          • Uterus

          References

          This article includes 15 references
          1. Beluche LA, Bertone AL, Anderson DE, Kohn CW, Weisbrode SE. In vitro dose-dependent effects of enrofloxacin on equine articular cartilage.. Am J Vet Res 1999 May;60(5):577-82.
            pubmed: 10328427
          2. Giguère S, Sweeney RW, Bélanger M. Pharmacokinetics of enrofloxacin in adult horses and concentration of the drug in serum, body fluids, and endometrial tissues after repeated intragastrically administered doses.. Am J Vet Res 1996 Jul;57(7):1025-30.
            pubmed: 8807015
          3. Kaartinen L, Panu S, Pyörälä S. Pharmacokinetics of enrofloxacin in horses after single intravenous and intramuscular administration.. Equine Vet J 1997 Sep;29(5):378-81.
            pubmed: 9306065doi: 10.1111/j.2042-3306.1997.tb03143.xgoogle scholar: lookup
          4. Bennett JV, Brodie JL, Benner EJ, Kirby WM. Simplified, accurate method for antibiotic assay of clinical specimens.. Appl Microbiol 1966 Mar;14(2):170-7.
            pubmed: 4959982doi: 10.1128/am.14.2.170-177.1966google scholar: lookup
          5. Giguère S, Bélanger M. Concentration of enrofloxacin in equine tissues after long-term oral administration.. J Vet Pharmacol Ther 1997 Oct;20(5):402-4.
            pubmed: 9350262doi: 10.1046/j.1365-2885.1997.00071.xgoogle scholar: lookup
          6. Spensley MS, Baggot JD, Wilson WD, Hietala SK, Mihalyi JE. Pharmacokinetics and endometrial tissue concentrations of ticarcillin given to the horse by intravenous and intrauterine routes.. Am J Vet Res 1986 Dec;47(12):2587-90.
            pubmed: 3800116
          7. Orsini JA, Park MI, Spencer PA. Tissue and serum concentrations of amikacin after intramuscular and intrauterine administration to mares in estrus.. Can Vet J 1996 Mar;37(3):157-60.
            pubmed: 8681283
          8. Giguère S, Sweeney RW, Habecker PL, Lucas J, Richardson DW. Tolerability of orally administered enrofloxacin in adult horses: a pilot study.. J Vet Pharmacol Ther 1999 Oct;22(5):343-7.
            pubmed: 10597539doi: 10.1046/j.1365-2885.1999.00224.xgoogle scholar: lookup
          9. Langston VC, Sedrish S, Boothe DM. Disposition of single-dose oral enrofloxacin in the horse.. J Vet Pharmacol Ther 1996 Aug;19(4):316-9.
            pubmed: 8866463doi: 10.1111/j.1365-2885.1996.tb00057.xgoogle scholar: lookup
          10. Dalhoff A, Weuta H. Penetration of ciprofloxacin into gynecologic tissues.. Am J Med 1987 Apr 27;82(4A):133-8.
            pubmed: 3555027
          11. McKellar Q, Gibson I, Monteiro A, Bregante M. Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration.. Antimicrob Agents Chemother 1999 Aug;43(8):1988-92.
            pubmed: 10428924doi: 10.1128/AAC.43.8.1988google scholar: lookup
          12. Van Camp SD, Papich MG, Whitacre MD. Administration of ticarcillin in combination with clavulanic acid intravenously and intrauterinely to clinically normal oestrous mares.. J Vet Pharmacol Ther 2000 Dec;23(6):373-8.
            pubmed: 11168915doi: 10.1046/j.1365-2885.2000.00297.xgoogle scholar: lookup
          13. Bermingham EC, Papich MG, Vivrette SL. Pharmacokinetics of enrofloxacin administered intravenously and orally to foals.. Am J Vet Res 2000 Jun;61(6):706-9.
            pubmed: 10850849doi: 10.2460/ajvr.2000.61.706google scholar: lookup
          14. Love CC, Strzemienski PJ, Kenney RM. Endometrial concentrations of ampicillin in mares after intrauterine infusion of the drug.. Am J Vet Res 1990 Feb;51(2):197-9.
            pubmed: 2301829
          15. Walker RD. The use of fluoroquinolones for companion animal antimicrobial therapy.. Aust Vet J 2000 Feb;78(2):84-90.
            pubmed: 10736664doi: 10.1111/j.1751-0813.2000.tb10528.xgoogle scholar: lookup

          Citations

          This article has been cited 0 times.
          Subscribe to our newsletter
          Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.